Frontier Medicines is leveraging a chemoproteomics platform to try to build a better KRAS G12C

blonca9
Mar 5, 2024
1 min read

Chris Varma describes why hitting KRAS G12C in both its on and off state could be an improvement over existing medicines. He also describes Frontier's platform and a recent $80M series C raise.

Recent Posts

See All

RBC Global Healthcare Conference: Korro Bio entered the clinic with its RNA editing platform in January and will have multiple cohorts of data in AATD later this year

RBC Global Healthcare Conference: With a phase 3 for its lead program scheduled to read in Q3 and mid-stage data for another program coming up this quarter, aTyr Pharma has pivotal months ahead

RBC Global Healthcare Conference: Ocular Therapeutix's Chairman & CEO Pravin Dugel provides an update on the progress of the pivotal studies for AXPAXLI in wet AMD

Frontier Medicines is leveraging a chemoproteomics platform to try to build a better KRAS G12C

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight